The t(10;11)(p13;q14-21) is a non-random translocation described in acute lymphoblastic and myeloid leukaemias. It results in the fusion of the gene CALM, which encodes a clathrin assembly protein, on 11q14 to the gene AF10, a putative transcription factor on 10p13. Here we describe for the first time, the occurrence of a CALM-AF10 fusion in a case of acute megakaryoblastic leukaemia. Fluorescence in situ hybridisation and reverse transcriptase polymerase chain reaction were used to confirm the presence of a CALM-AF10 fusion. A novel splice variant of CALM missing nt 1927-2091 was also detected. Though CALM is a cytoplasmic protein, the chimaeric fusion product is able to localise to both the nucleus and cytoplasm. Analysis of the fusion variants suggests, however, that the critical fusion product is likely to be cytoplasmic and contain the interactive leucine zipper of AF10. Leukemia (2001) 15, 910-914.
Introduction
The non-random t(10:11)(p13;q23) and t(10:11)(p13;q14-21) translocations described in acute leukaemias results in rearrangements of the AF10 gene on 10p13, 1 fusing it to the MLL gene on 11q23 or the CALM gene on 11q14.
1,2 MLL undergoes fusions with many genes, 3, 4 but the critical fusion product contains the N-terminus region of MLL, which contains nuclear localisation signals, AT hooks and a methyltransferase-like domain. The highly conserved cysteine-rich LAP/PHD zinc fingers 5 and the SET domain 3 are lost as a result of the translocation. AF10 has a LAP/PHD finger followed by a cysteine-rich region called the E-LAP domain at its N-terminus end. 6 As shown in Figure 1a , further characterisation of AF10 has revealed, sequentially downstream from the cysteine-rich region, a bipartite nuclear localisation signal, a functional AThook motif, an interactive leucine zipper and a Q-rich domain towards the carboxy-terminus. 7 The AF10 protein localises to both the nucleus and cytoplasm. 7 The CALM gene product has an N-terminus conserved domain that is homologous to the AP-3 type of clathrin binding proteins, 2, 8 and localises to the plasma membrane-coated pits and the Golgi apparatus. The C-terminus end of CALM binds the terminal domain of the clathrin heavy chain, although the full-length protein appears to be necessary for maximum interactability. 8 CALM appears to be an important component of the coated pit internalisation machinery, possibly involved in the regulation of clathrin recruitment to the membrane and/or the formation of a coated pit. 8 The breakpoints in CALM are towards the 3Ј end resulting in almost the entire length of CALM fused to various lengths of AF10 in CALM-AF10 fusion products. [9] [10] [11] [12] [13] [14] [15] Unlike the MLL-AF10 fusion, which appears to be associated with differentiated acute myeloid leukaemias (AML), mainly FAB M4 and M5, CALM-AF10 fusions are mainly identified in T cell acute lymphoblastic leukaemias (ALL) and undifferentiated AML (FAB M0 or M1). Recently it has also been reported in cases of FAB M5 AML. 10, 14 In this paper we report the identification of a CALM-AF10 fusion in a case of megakaryocytic AML (FAB M7) where the diagnosis was initially obscured by a concomitant malaria infection and discuss the effects of the fusion product on the basis of current knowledge.
Case report
A 6-year-old boy from the Ivory Coast presented with a 5-day history of fever and malaise. He had received oral quinine 2 months previously for a presumptive malaria infection, while still in the Ivory Coast. He appeared well and physical examination was unremarkable. Blood indices showed a haemoglobin of 8.7 g/dl, a white cell count of 3.6 × 10 9 cells/l (absolute neutrophil count of 1.4) and a platelet count of 8 × 10 9 /l. Examination of the peripheral blood film showed the presence of reactive lymphocytes and Plasmodium falciparum parasites at a density of 0.5%. Additional laboratory investigations included tests for sickle cell disease that were negative, glucose-6-phosphate dehydrogenase level that was normal and there was no evidence of active Epstein-Barr or human immunodeficiency virus infection. He was treated with quinine for 7 days and a single dose of pyrimethamine/ sulfadoxine (Fansidar). A repeat full blood count 1 week later showed haemoglobin of 9.1 g/dl, a white cell count of 7.4 × 10 9 cells/l (absolute neutrophil count of 2.3) and platelets of 25 × 10 9 cells/l. Parasitaemia was no longer evident on the peripheral blood film. The peripheral blood white cell surface marker profile showed an increase of CD8 (32%) positive cells and a population of CD34 (7%) positive cells that coexpressed CD33/16. Examination of the bone marrow aspirate showed a reduction in trilineage haematopoiesis with a marked reduction in megakaryocytes. A moderate degree of lymphoid infiltration was noted with some reactive and atypical forms showing cytoplasmic blebs. No obvious blasts were seen.
Cytogenetic studies on peripheral blood revealed a clonal proliferation of cells with karyotype 47, XY, t(10;11)(p13;q14-22), del (13) (q12-14q22), +20 [9] /46, XY [10] . A repeat bone marrow aspirate 9 days after initial presentation showed diffuse infiltration with featureless blasts, decreased granulocytes and small dysmorphic megakaryocytes. Flow cytometric analysis of the marrow showed that the blasts were CD13 (13%), CD33 (85%), CD42a&b 76%, CD61 (79%) and glycophorin A (29%) positive. Cytogenetic G-banding confirmed the presence of the same stemline clone as identified in the peripheral blood together with a sideline clone containing a deletion of the long arm of chromosome 20 del(20q). A diagnosis of AML-M7 by the French-American-British (FAB) classification was made. The patient was commenced on the UK AML 12 protocol consisting of two induction courses of mitozantrone, cytarabine and etoposide followed by consolidation with one course of amsacrine, cytarabine and etoposide and finally mitozantrone and high-dose cytarabine. The bone marrow was shown to be in morphological remission prior to the second induction course.
Materials and methods

Southern blotting analyses
To search for MLL gene rearrangements, a Southern blot containing BamHI, EcoRI and HindIII digested genomic DNA obtained from leukaemic cells, was hybridised with a cDNA probe spanning MLL exons 5-10 (residues 3690-4314). All restriction buffers, bovine serum albumin (BSA), and restriction enzymes were from New England Biolabs (Hitchin, UK).
Cloning and sequencing
One g of total RNA extracted from fresh and cryopreserved bone marrow using RNAzol B (Biogenesis, Poole, UK) was reverse transcribed to cDNA in a reaction mixture containing 50 mM Tris, 75 mM KCl, 3 mM MgCl 2 0.2 mM each dNTP, Leukemia 10 g/l random hexamers, 10 g BSA, 20 U RNAsin (Promega, Southampton, UK) and 200 U Superscript (GIBCO BRL, Paisley, UK) reverse transcriptase, in a volume of 20 l. The sample was incubated at 37°C for 1 h. Nested PCR was performed to detect the fusion mRNAs of AF10 and CALM. First round PCR to detect the AF10-CALM fusion transcript, was carried out using AF10 ext/sens: 5Ј-CAGACG AGAGAGGCTGGGCCGAGAA-3Ј CALM ext/antis: 5Ј-GTAGCATCCTAATGGAAGAAGAGAG-3. Nested PCR reactions were carried out with primers AF10 int/sens: 5Ј-TGGTTTATTGCGACGGGCACGGCTG-3Ј and CALM int/ antis: 5Ј-AGTAAGGATTTTGCTGCTTGAGCAC-3Ј. To detect CALM-AF10 fusion transcripts first round PCR was carried out with CALMext/sens: 5Ј-CTTGGCATCGGAAATGGAACCA CTA-3Ј and AF10ext/antis: 5Ј-TAACGATCATGCGGAACA-GACTGTA-3Ј and nested PCR performed using primers CALMint/sens: 5Ј-TGATGTAAATTGGAGTCAACCAGGT-3Ј and AF10int/antis: 5Ј-ATTGTACCTCTGGAATATACAGGGC-3Ј. PCR reactions were set up using 2 l of the resulting cDNA in a reaction mix containing 10 mM Tris, 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM each dNTP, 2 mM of each appropriate primer 1 U Taq polymerase (ICRF Laboratories, London, UK). Amplifications were performed in a PTC-225 Peltier Thermal Cycler for 35 cycles (94°C for 30 s, 56°C for 30 s, 72°C for 30 s), and the resulting products visualised on a 2% (wt/vol) agarose gel. PCR products were then cloned using the TA Cloning kit (Invitrogen, Paisley, UK) and E. coli transformed according to the manufacturer's instructions. A total of six independent colonies were analysed for each ligation by restriction endonu-Leukemia clease digestion. Sequencing was carried on 0.5 g of plasmid DNA by cycle sequencing using the Applied Biosystems (Warrington, UK) dye-deoxy terminator sequencing kit and samples run on a Perkin Elmer ABI Prism 377 DNA sequencer. Database searches were performed using the BLAST algorithm through http://www.ncbi.nlm.nih.gov/BLAST.
Chromosomal analyses
G-banded analysis was performed on metaphases derived from both the bone marrow aspirate and the fine needle aspirate. Briefly, cultures were initiated with 1 × 10 6 cells/ml and incubated at 37°C for 72 h. Colcemid was added and the cells harvested according to standard protocols. 16 Metaphases were G banded using trypsin and Leishman's stain and 10 metaphases were fully analysed.
Fluorescent in situ hybridisation (FISH) was performed on fixed metaphases prepared as described above using a probe for the MLL gene (Vysis, Richmond, UK) and the CALM gene (PAC576E10) (Figure 2 ). CALM cDNA corresponding to residues (1827-2144) 2 was used to probe a PAC library. A single clone (PAC576E10) was isolated and confirmed by rehybridisation with the original cDNA clone and mapped to 11q14 by FISH. The CALM probe was labelled by nick translation with Spectrum Red (Vysis, UK) according to the manufacturer's instructions.
Results
Cytogenetic studies
Conventional G-banded cytogenetic analysis performed on the patient's peripheral blood sample, showed an abnormal clone containing a t(10;11)(p13;q14-21), a (del)13q and trisomy 20. The same stemline clone was identified from the
Figure 2
FISH analysis of the metaphase cell hybridised with a CALM probe PAC576E10. Arrowheads indicate the position of three red signals for PAC576E10: on the normal chromosome 11 (nl 11), on the der (10) and on the der (11). marrow as identified in the peripheral blood together with a sideline clone containing a deletion of 20q (47, XY, t(10;11)(p13;q14-22), del (13) (q12-14q22), +20 [9] /47, idem, del (20) (q11.2q13.3) [2] /46, XY [10] ), in addition to the stemline abnormalities. There was no evidence of a MLL rearrangement by FISH (data not shown). The CALM probe, however, showed a split signal on the der (11) and der (10), confirming the involvement of the CALM gene in the t(10;11) (Figure 2 ).
Molecular analysis
Southern analysis of the leukaemic cells showed a germline pattern for the MLL gene, confirming the FISH results (data not shown) and supported the possibility of a CALM-AF10 fusion. As shown in Figure 1b , reverse transcriptase polymerase chain reaction (RT-PCR) analysis confirmed the presence of both a CALM:AF10 and a reciprocal AF10:CALM transcript from the diagnostic marrow sample and both transcripts were still detectable at the end of the treatment. Cloning and sequencing of the amplified PCR products revealed that fusion of the CALM:AF10 occurred at nucleotide position 1926 of the CALM cDNA 2 and position 424 of the AF10 sequence.
1
The reciprocal transcript fused AF10 423 to CALM 1987 and not to the expected CALM 1927. This variation is likely to be due to an alternatively spliced exon (1927-1986) of CALM, which has been previously described by others. 10, 13, 14 Additionally, wild-type (WT) AF10 cDNAs from this patient were amplified and sequenced. We were unable however, to detect the full length WT CALM in any of the samples analysed, instead all samples sequenced were found to contain a novel splice variant, missing nucleotides 1927-2091 thought to be encoded by two adjacent exons 16 ( Figure 1c ). This new variant WT CALM cDNA encodes a protein lacking amino acids 594-648 of the originally described protein. 
Discussion
This case illustrates the difficulty in making a diagnosis of AML when the presentation is masked by infection, in this case malaria. Plasmodium falciparum infections are associated with trilineage dysplasia in particular thrombocytopenia 17 and the earliest diagnostic index for this case was the result of cytogenetic analysis on the peripheral white blood cells. Previously published chromosomal abnormalities in AML M7 have included the t(10;11)(p12;q23) translocation which results in a MLL-AF10 fusion 18 and the t(1;22)(p13;q13) seen mainly in infants. 19 To the best of our knowledge, this is the first report of a patient with a fusion involving the t(10;11)(p12;q14-22) chromosomal region in a patient with AML M7 involving CALM:AF10. With this description of the fusion in AML M7, it is clear that CALM-AF10 fusions are not specific for any subtype of leukaemia.
While the CALM-AF10 fusion is constantly detected in all reported cases, the reciprocal AF10-CALM product does not always appear to be present. This suggests that the critical fusion product is the 5Ј fusion of CALM gene to the 3Ј end of AF10. This is in contrast to the MLL-AF10 fusion where we have never been able to detect a reciprocal AF10-MLL transcript. 20 There is a simple explanation for this. MLL and AF10 are transcribed in opposite directions to each other, MLL being 5Ј centromeric and 3Ј telomeric while AF10 is 5Ј telomeric and 3Ј centromeric in orientation. 21 Therefore complex chromosomal rearrangements are necessary for a 5ЈMLL-3ЈAF10 fusion to occur and a transcribable reciprocal fusion is unlikely. 22, 23 CALM is, however, transcribed in the same orientation as AF10, and a legitimate reciprocal translocation is more likely to occur.
Of interest then are the various CALM-AF10 fusions that have been detected and classified as types I-V.
14 Three breakpoints for CALM have been described in the CALM-AF10 fusion, at nt 1926/1927, nt 1986/1987 and nt 2091/2092. As we have shown in this paper, aa 594-648 are coded for by two exons which are alternatively spliced in the WT and would also be absent from the CALM-AF10 fusion product. The importance of these residues to the interaction of CALM with clathrin 8 is unknown. Functionally the different breakpoints in CALM are a manifestation of alternative splicing and are unlikely to lead to a different functional product. This is not the case for AF10 however. The described breakpoints in AF10 in the CALM-AF10 fusion include nt 424/425, 589/590, 883/884 and 979/980. As shown in Figure 1a and Table 1 , depending on where the breakpoints are the fusion product will retain or lose some of the interactive domains of AF10.
The CALM-AF10 424 product, together with the 590 fusion protein lacks the dimerising LAP/PHD finger domain but retains the bipartite nuclear localisation signal (NLS). 6 Indeed, as expected immunocytochemistry localises the CALM-AF10 product to both the nucleus and cytoplasm in the U937 cell line (unpublished observation). The result of both the CALM-AF10 883 and CALM-AF10 979 breakpoint is the loss of the N-terminal cysteine-rich region and the bipartite NLS. We predict as a result, that these fusion products will localise to the cytoplasm. A green fluorescent tagged CALM-AF10 fusion product has been reported to be detected in the cytoplasm when expressed in NIH3T3 fibroblasts. 9 Unfortunately data as to the fusion site were not presented and we are unable to comment on whether this fusion product contained an intact NLS. However, as with all the CALM-AF10 chimaeras, the AThook, leucine zipper and Q-rich domain are retained.
As shown in Table 1 , not all fusion products will be relocated to the nucleus as wild-type AF10 is also expressed in the cytoplasm. The relatively even distribution of patients over the four described AF10 breakpoints suggests that, irrespective of the positioning of the NLS within the CALM-AF10 fusion, it is the cytoplasmic chimaeric protein that is critical for transformation. The functions of both proteins and their fusion products are therefore required for a better understanding of the normal cellular process, as well as that of leukaemogenesis. 
